🚀 VC round data is live in beta, check it out!
Unicycive Valuation Multiples
Discover revenue and EBITDA valuation multiples for Unicycive and similar public comparables like Tetratherix, Artiva Biotherapeutics, Nkarta, Immunic and more.
Unicycive Overview
About Unicycive
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Founded
2016
HQ
Employees
23
Website
Sectors
Financials (LTM)
EV
$127M
Unicycive Financials
Unicycive reported last 12-month revenue of $13M.
In the same LTM period, Unicycive generated $11M in gross profit and had net loss of ($21M).
Revenue (LTM)
Unicycive P&L
In the most recent fiscal year, Unicycive reported revenue of — and EBITDA of ($26M).
Unicycive expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $13M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $11M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($26M) | XXX | XXX | XXX |
| EBIT Margin | (160%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($21M) | XXX | ($27M) | XXX | XXX | XXX |
| Net Margin | (166%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Unicycive Stock Performance
Unicycive has current market cap of $168M, and enterprise value of $127M.
Market Cap Evolution
Unicycive's stock price is $6.65.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $127M | $168M | 3.1% | XXX | XXX | XXX | $-1.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialUnicycive Valuation Multiples
Unicycive trades at 9.8x EV/Revenue multiple, and (4.9x) EV/EBITDA.
EV / Revenue (LTM)
Unicycive Financial Valuation Multiples
As of April 11, 2026, Unicycive has market cap of $168M and EV of $127M.
Equity research analysts estimate Unicycive's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Unicycive has a P/E ratio of (7.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $168M | XXX | $168M | XXX | XXX | XXX |
| EV (current) | $127M | XXX | $127M | XXX | XXX | XXX |
| EV/Revenue | 9.8x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.9x) | XXX | XXX | XXX |
| EV/EBIT | (6.1x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 11.6x | XXX | — | XXX | XXX | XXX |
| P/E | (7.8x) | XXX | (6.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Unicycive Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Unicycive Margins & Growth Rates
Unicycive's revenue in the last 12 month grew by 1067%.
Unicycive's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
Unicycive Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1067% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (28%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 53% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 169% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 73% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Unicycive Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tetratherix | XXX | XXX | XXX | XXX | XXX | XXX |
| Artiva Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nkarta | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunic | XXX | XXX | XXX | XXX | XXX | XXX |
| Whitehawk Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Unicycive M&A Activity
Unicycive acquired XXX companies to date.
Last acquisition by Unicycive was on XXXXXXXX, XXXXX. Unicycive acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Unicycive
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialUnicycive Investment Activity
Unicycive invested in XXX companies to date.
Unicycive made its latest investment on XXXXXXXX, XXXXX. Unicycive invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Unicycive
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Unicycive
| When was Unicycive founded? | Unicycive was founded in 2016. |
| Where is Unicycive headquartered? | Unicycive is headquartered in United States. |
| How many employees does Unicycive have? | As of today, Unicycive has over 23 employees. |
| Who is the CEO of Unicycive? | Unicycive's CEO is Shalabh Gupta. |
| Is Unicycive publicly listed? | Yes, Unicycive is a public company listed on Nasdaq. |
| What is the stock symbol of Unicycive? | Unicycive trades under UNCY ticker. |
| When did Unicycive go public? | Unicycive went public in 2021. |
| Who are competitors of Unicycive? | Unicycive main competitors are Tetratherix, Artiva Biotherapeutics, Nkarta, Immunic. |
| What is the current market cap of Unicycive? | Unicycive's current market cap is $168M. |
| What is the current revenue of Unicycive? | Unicycive's last 12 months revenue is $13M. |
| What is the current revenue growth of Unicycive? | Unicycive revenue growth (NTM/LTM) is 1067%. |
| What is the current EV/Revenue multiple of Unicycive? | Current revenue multiple of Unicycive is 9.8x. |
| Is Unicycive profitable? | No, Unicycive is not profitable. |
| What is the current net income of Unicycive? | Unicycive's last 12 months net income is ($21M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.